Skip to main content

Xbryk News

Monthly News Roundup - February 2025

FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (de...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Xbryk patient information at Drugs.com